The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Share News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.10 (6.667%)
Open: 1.55
High: 1.55
Low: 1.55
Prev. Close: 1.55
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Feedback And Tissue Regenix Secure CE Marks

Mon, 01st Jun 2020 15:54

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Feedback PLC - medical imaging - Says its Bleepa imaging technology achieves CE mark, a European Union regulatory award. Adds mark gives healthcare providers confidence in Bleepa product.

----------

Tissue Regenix Group PLC - medical devices - Secures CE mark for OrthoPure XT tissue regeneration product.

----------

Arix Bioscience PLC - biotech investor - Says portfolio company Iterum Therapeutics PLC failed to meet the primary endpoint in study for Sulopenem as treatment for urinary tract infection.

----------

Hutchison China Meditech Ltd - pharmaceuticals - Plans to submit new drug application to US regulators for Surufatinib medication for cancer treatment. Planned start of new drug submission is late 2020. Notes US Food & Drug Administration in April gave Surufatinib fast track designation for development of neuroendocrine tumours in non-pancreatic and pancreatic medication.

----------

IQ-AI Ltd - medical software - Reports Imaging Biometrics subsidiary awarded USD2.6 million US grant in collaboration with Barrow Neurological Institute, the Mayo Clinic and the Medical College of Wisconsin. Funding to go towards research of brain tumour treatment response.

----------

LiDCO Group PLC - hemodynamic monitoring - Benefitted from increased demand in first quarter due to Covid-19 pandemic, but reports "exceptional conditions" have since eased somewhat. Adds that signs are suggesting number of elective surgeries returning to pre-pandemic levels and company's sales for May in-line with last year.

----------

EQTEC PLC - energy project technology provider - Strikes deal with lenders Altair Group Investment Ltd and Riverfort Global Opportunities PCC Ltd to extend maturity date of debts to June 30, 2021.

----------

Xeros Technology Group PLC - water filtration - Completes sale of Marken business after disposal was previously delayed by Covid-19 pandemic. Final cash consideration totalled GBP175,000.

----------

Gama Aviation PLC - aviation services - Awarded contract by UK Home Office to complete electronic devices testing on several emergency services aircrafts.

----------

Transense Technologies PLC - sensor systems - Extends exclusivity for collaboration agreement with Bridgestone Corp for installation of tyre monitoring systems.

----------

Amur Minerals Corp - nickel-copper sulphide explorer - Reports copper and nickel sulphide concentrates can be generated at Kun-Manie project, Russia. Says out of 6.0 million tonnes of ore processed per annum, copper concentrate of 39,300 tonnes is expected to be produced, at average grade of just over 23%.

----------

Independent Oil & Gas PLC - development and production - Awards core project phase 1 well management contract at UK southern North Sea assets to Petrofac.

----------

Atalaya Mining PLC - miner - Says regional government of Andalusia confirms through Spanish press that it has validated Atalaya's mining permits at Riotinto project.

----------

Star Phoenix Group Ltd - oilfield services - Grants LandOcean Energy Services Co Ltd extension to provide remaining USD459,970 cash in relation to sale of Range Resources Trinidad Ltd.

----------

Savannah Resources PLC - energy metals - Submits environmental impact assessment and mine plan for Mina do Barroso lithium project in Portugal.

----------

Rockfire Resources PLC - gold exploration - Says rock sampling results find new gold targets at Lighthouse tenement in Australia. Reports 15 rocks were collected from Cardigan Dam, with 47% returning gold values above 0.5 grammes per tonne.

----------

IronRidge Resources Ltd - mineral exploration - Says infill soil sampling at Zaranou gold project in Cote d'Ivoire confirms and enhances gold anomalies at asset.

----------

PowerHouse Energy Group PLC - hydrogen production - Not aware of any material reason for recent share price increase. Says continuing to manage operating costs and cash balances stand at GBP280,000, enough to meet outstanding cash burn until fourth quarter.

----------

AFC Energy PLC - hydrogen generation - Partners with Spanish infrastructure firm ACCIONA SA to test AFC's H-Power fuel cell platform which aims to decarbonise construction sites in Europe.

----------

Beowulf Mining PLC - mineral exploration - Says soil sampling at Vardar, Kosovo has found "extensive" gold anomaly over an area of roughly 1,4000 metres by 700 metres. Beowulf finalising plans for geophysical surveys once Covid-19 restrictions allow.

----------

Emmerson PLC - potash development - Completes feasibility study at Khemisset potash project, Morocco. Study finds posttax net present value with 8% discount of USD1.4 billion and pre-production costs of USD387 million.

----------

Danakali Ltd - potash mining - Agrees to extend deadline for tranche two of Colluli Sulphate of Potash project equity funding from Africa Finance Corp. Deadline extended to on or before November 31, in response to Covid-19 restrictions.

----------

Columbus Energy Resources PLC & Predator Oil & Gas Holdings PLC - oil and gas - Confirm start of phase 2 of carbon dioxide pilot project in Trinity Inniss field, Trinidad.

----------

Strategic Minerals PLC - minerals company - Says subsidiary Southern Minerals Group awarded USD21.9 million in damages over legal proceedings related to the Cobre mine.

----------

Trinity Exploration & Production PLC - exploration and production - Receives VAT bonds totalling USD2.8 million from Trinidad & Tobago government. Plans to sell bonds to local financial institution.

----------

Xtract Resources PLC - miner - Concludes deal to acquire Bushranger copper and gold project owner ProsepectOre Ltd for USD1.3 million in shares.

----------

Picton Property Income Ltd - property investor - Finalises USD50 million revolving credit facility to replace two existing loans which were due to expire in June 2021. The new facility has three-year initial term with option of two one-year extensions. Will incur interest at 150 basis points over LIBOR.

----------

Dods Group PLC - events - Says lender Barclays Bank agrees to waive all covenants for remainder of financial year in light of Covid-19 uncertainty.

----------

Warpaint London PLC - colour cosmetics producer - Agrees deal to stock its products at UK retail firm Wilko. From mid-September, roughly 100 Body Collection-branded productions will be stocked at 355 Wilko stores.

----------

Codemasters Group Holdings PLC - video game developer - Strikes licence agreement deal for exclusive rights to develop FIA World Rally Championship games and esports tournaments.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more
10 Jan 2024 11:48

IQ-AI falls after subsidiary notes launch of treatment access scheme

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.

Read more
19 Dec 2023 17:00

IQ-AI firm gets US FDA fast-track status for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Tuesday said the US Food & Drug Administration has granted 'fast-track" designation for oral gallium maltolate, which is its subsidiary Imaging Biometrics LLC's therapeutic for the treatment of adult patients with relapsed or refractory glioblastoma.

Read more
5 Dec 2023 11:49

IQ-AI stock rises on positive interim results from glioblastoma trial

(Alliance News) - IQ-AI Ltd on Tuesday reported positive results from Phase 1 of an on-going study for its investigational monotherapy oral gallium maltolate.

Read more
8 Nov 2023 12:04

IQ-AI says Imaging Biometrics submits paediatric rare disease request

(Alliance News) - IQ-AI Ltd on Wednesday said its wholly-owned subsidiary Imaging Biometrics LLC has submitted a paediatric rare disease request to the US Food & Drug Administration for its gallium maltolate therapy.

Read more
18 Oct 2023 17:11

IN BRIEF: IQ-AI subsidiary "central" to "landmark" brain cancer study

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Notes its wholly-owned subsidiary, Imaging Biometrics LLC (IB), has announced the results of a "landmark" study. Says the study represents the first large-scale characterization of the invasive tumour margins of high-grade glioma using multi-regional genomic/transcriptomic sequencing with spatially matched MRI measurements in glioma. High-grade glioma is a deadly brain cancer. Explains that Imaging Biometrics' IB Neuro's dynamic susceptibility contrast magnetic resonance imaging software was central to the study.

Read more
9 Oct 2023 12:09

IN BRIEF: IQ-AI subsidiary wins orphan drug designation from US FDA

IQ-AI Ltd - St Helier, Jersey-based medical services firm focused on cancer treatment - Wholly-owned subsidiary Imaging Biometrics LLC is granted an orphan drug designation from the US Food & Drug Administration for gallium maltolate for the treatment of atypical teratoid rhabdoid tumour. Notes this is the second orphan designation granted to gallium maltolate this year.

Read more
8 Sep 2023 10:25

IQ-AI notes vindication of subsidiary's reduced gadolinium approach

(Alliance News) - IQ-AI Ltd on Friday noted that studies by its subsidiary Imaging Biometrics LLC validated the dosing approach of Imaging's MRI-focused IB Neuro.

Read more
18 Aug 2023 12:17

IQ-AI shares jump on subsidiary's GE Healthcare deal

(Alliance News) - IQ-AI Ltd on Friday said its wholly-owned subsidiary Imaging Biometrics LLC has signed a deal with GE HealthCare Technologies Inc.

Read more
17 Aug 2023 11:21

IQ-AI interim loss narrows amid higher revenue, lower expenses

(Alliance News) - IQ-AI Ltd on Thursday announced a slightly lower loss for the six months to June 30, as revenue was up and administrative expenses were lower.

Read more
19 Jul 2023 10:45

IN BRIEF: IQ-AI subsidiary's app adopted by US medical college

IQ-AI Ltd - Jersey-based medical services firm focused on cancer treatment - Says subsidiary Imaging Biometrics LLC's handheld application IB Nimble has been adopted by the Medical College of Wisconsin's Orthopedic Department for use in bone metastases treatment. IB Nimble's designer, Joseph Bovi, is professor of radiation oncology & neurosurgery at MCW. The application was originally designed to help treat brain metastases. IQ-AI says it "provides real-time collaboration amongst multi-disciplinary teams" to "provide optimised treatments faster". Josh McComack, Imaging Biometrics' director of software engineering, says the new installation "demonstrates that IB Nimble is ready for widespread deployment."

Read more
13 Jul 2023 11:36

IN BRIEF: IQ-AI granted orphan drug designation for Gallium Galtolate

IQ-AI Ltd on Thursday - Jersey-based incubator of software and other tools for the treatment of cancer - IQ-AI subsidiary Imaging Biometrics LLC has been granted an orphan drug designation for Gallium Galtolate for the treatment of paediatric glioblastoma multiforme, or GBM, by the US Food & Drug Administration. Says GBM is the most common and aggressive primary brain tumour in adults and children. Imaging Biometrics' application to the FDA was first submitted in April. In June, two pre-clinical studies showed oral GaM inhibits brain tumour growth in children, and the results were consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin.

Read more
27 Jun 2023 11:47

IN BRIEF: IQ-AI notes Gallium Moltate studies on tumour growth

IQ-AI Ltd - Jersey-based medical services firm - Says subsidiary Imaging Biometrics LLC's two new pre-clinical studies show oral Gallium Maltolate inhibits brain tumour growth in children. Says the results are consistent with previous work conducted in the Schmainda Lab at the Medical College of Wisconsin. This follows IB's application for Orphan Drug Designation to the US Food & Drug Administration back in April for the use of GaM in pediatric brain tumours. Notes application is currently under review.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.